CY1122584T1 - Συγχορηγηση ενος παραγοντα που συνδεεται με ενα τατ πεπτιδιο εσωτερικοποιησης με εναν αναστολεα αποκοκκιωσης μαστοκυτταρων - Google Patents
Συγχορηγηση ενος παραγοντα που συνδεεται με ενα τατ πεπτιδιο εσωτερικοποιησης με εναν αναστολεα αποκοκκιωσης μαστοκυτταρωνInfo
- Publication number
- CY1122584T1 CY1122584T1 CY20191101350T CY191101350T CY1122584T1 CY 1122584 T1 CY1122584 T1 CY 1122584T1 CY 20191101350 T CY20191101350 T CY 20191101350T CY 191101350 T CY191101350 T CY 191101350T CY 1122584 T1 CY1122584 T1 CY 1122584T1
- Authority
- CY
- Cyprus
- Prior art keywords
- internalizing peptide
- tat
- mast cell
- inhibitor
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18594309P | 2009-06-10 | 2009-06-10 | |
| PCT/US2010/038226 WO2010144742A2 (en) | 2009-06-10 | 2010-06-10 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122584T1 true CY1122584T1 (el) | 2021-01-27 |
Family
ID=43309471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101350T CY1122584T1 (el) | 2009-06-10 | 2019-12-23 | Συγχορηγηση ενος παραγοντα που συνδεεται με ενα τατ πεπτιδιο εσωτερικοποιησης με εναν αναστολεα αποκοκκιωσης μαστοκυτταρων |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8933013B2 (https=) |
| EP (2) | EP3682895A1 (https=) |
| JP (5) | JP5886192B2 (https=) |
| AU (1) | AU2010259986B2 (https=) |
| CA (2) | CA2765171C (https=) |
| CY (1) | CY1122584T1 (https=) |
| DK (1) | DK2440231T3 (https=) |
| ES (1) | ES2765281T3 (https=) |
| HR (1) | HRP20192230T1 (https=) |
| HU (1) | HUE046640T2 (https=) |
| LT (1) | LT2440231T (https=) |
| PL (1) | PL2440231T3 (https=) |
| PT (1) | PT2440231T (https=) |
| SI (1) | SI2440231T1 (https=) |
| SM (1) | SMT202000056T1 (https=) |
| WO (1) | WO2010144742A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| DK2320927T3 (en) * | 2008-07-09 | 2015-09-14 | Univ Copenhagen | Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction |
| EP3682895A1 (en) | 2009-06-10 | 2020-07-22 | NoNO Inc. | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
| PH12012500565B1 (en) | 2009-09-22 | 2018-01-12 | Medicago Inc | Method of preparing plant-derived proteins |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| ES2912042T3 (es) | 2011-06-24 | 2022-05-24 | Nono Inc | Terapia de combinación para isquemia |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| CA2892965C (en) * | 2012-11-28 | 2021-06-01 | Nono Inc. | Lyophilized formulation of tat-nr2b9c |
| WO2016172219A1 (en) * | 2015-04-24 | 2016-10-27 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation |
| AU2016382134B2 (en) | 2015-12-28 | 2022-09-22 | Idemitsu Kosan Co., Ltd. | Peptide tag and tagged protein including same |
| KR102403089B1 (ko) * | 2017-07-05 | 2022-06-02 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도 |
| HRP20250272T1 (hr) | 2017-10-19 | 2025-04-25 | Teijin Pharma Limited | Derivati benzimidazola i njihova uporaba |
| US20230055441A1 (en) * | 2020-01-09 | 2023-02-23 | Nono Inc. | Plasmin-resistant peptides for treating stroke and related conditions |
| US20240301003A1 (en) | 2021-01-08 | 2024-09-12 | Nono Inc. | Plasmin-resistant peptides for improved therapeutic index |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| EP1159418A2 (en) | 1998-12-11 | 2001-12-05 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US20040226056A1 (en) | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| DE60026313D1 (de) | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| CA2381425A1 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| US6887687B2 (en) | 2001-07-30 | 2005-05-03 | Immunex Corporation | Nucleic acids encoding human ataxin-1-like polypeptide IMX97018 |
| WO2004045535A2 (en) * | 2002-11-14 | 2004-06-03 | Arbor Vita Corporation | Molecular interactions in neurons |
| EP1601380A1 (en) | 2003-02-13 | 2005-12-07 | Licentia OY | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| US20050209141A1 (en) * | 2003-10-17 | 2005-09-22 | Silver Randi B | Mast cell-derived renin |
| US20050256065A1 (en) * | 2004-01-26 | 2005-11-17 | Permasight | Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents |
| US7151084B2 (en) | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| KR101384572B1 (ko) | 2005-12-30 | 2014-04-24 | 아버 비타 코포레이션 | Ｐｄｚ 상호작용의 소형 분자 억제제 |
| DK2043671T3 (da) * | 2006-07-11 | 2020-06-15 | Nono Inc | Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| ES2446292T3 (es) | 2007-03-02 | 2014-03-07 | Nono Inc. | Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N |
| WO2009006611A1 (en) | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| CN101842107B (zh) | 2007-07-26 | 2014-04-23 | 雷文斯治疗公司 | 抗微生物肽，组合物和使用方法 |
| ES2328776B1 (es) | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| DK2320927T3 (en) | 2008-07-09 | 2015-09-14 | Univ Copenhagen | Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction |
| EP3682895A1 (en) * | 2009-06-10 | 2020-07-22 | NoNO Inc. | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
-
2010
- 2010-06-10 EP EP19210675.5A patent/EP3682895A1/en not_active Withdrawn
- 2010-06-10 LT LTEP10786870.5T patent/LT2440231T/lt unknown
- 2010-06-10 HR HRP20192230TT patent/HRP20192230T1/hr unknown
- 2010-06-10 AU AU2010259986A patent/AU2010259986B2/en not_active Ceased
- 2010-06-10 DK DK10786870.5T patent/DK2440231T3/da active
- 2010-06-10 CA CA2765171A patent/CA2765171C/en active Active
- 2010-06-10 EP EP10786870.5A patent/EP2440231B1/en active Active
- 2010-06-10 ES ES10786870T patent/ES2765281T3/es active Active
- 2010-06-10 JP JP2012515161A patent/JP5886192B2/ja not_active Expired - Fee Related
- 2010-06-10 SM SM20200056T patent/SMT202000056T1/it unknown
- 2010-06-10 CA CA3018494A patent/CA3018494C/en active Active
- 2010-06-10 WO PCT/US2010/038226 patent/WO2010144742A2/en not_active Ceased
- 2010-06-10 PL PL10786870T patent/PL2440231T3/pl unknown
- 2010-06-10 HU HUE10786870A patent/HUE046640T2/hu unknown
- 2010-06-10 SI SI201031965T patent/SI2440231T1/sl unknown
- 2010-06-10 US US13/377,519 patent/US8933013B2/en active Active
- 2010-06-10 PT PT107868705T patent/PT2440231T/pt unknown
-
2014
- 2014-12-29 US US14/585,028 patent/US9433685B2/en not_active Expired - Fee Related
-
2015
- 2015-07-03 JP JP2015134712A patent/JP6238934B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-24 US US15/245,693 patent/US10046060B2/en active Active
-
2017
- 2017-09-19 JP JP2017179192A patent/JP6775478B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-12 US US16/034,235 patent/US20190038760A1/en not_active Abandoned
-
2019
- 2019-12-23 CY CY20191101350T patent/CY1122584T1/el unknown
-
2020
- 2020-04-17 JP JP2020074428A patent/JP7209364B2/ja active Active
-
2022
- 2022-10-25 JP JP2022170797A patent/JP2023017813A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122584T1 (el) | Συγχορηγηση ενος παραγοντα που συνδεεται με ενα τατ πεπτιδιο εσωτερικοποιησης με εναν αναστολεα αποκοκκιωσης μαστοκυτταρων | |
| CY1122674T1 (el) | Αντι-c5α συνδετiκα μορια με υψηλου βαθμου δραστiκοτητα αποκλεισμου | |
| CY1114608T1 (el) | Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου | |
| CY1124071T1 (el) | Συζευγμα αντισωματος anti-her3 φapmakoy | |
| CY1112215T1 (el) | Πιμοβενδανη που θα χρησιμοποιηθει για τη μειωση του μεγεθους της καρδιας σε θηλαστικα που υποφερουν απο καρδιακη ανεπαρκεια | |
| CY1121853T1 (el) | Συνδυαστικη θεραπεια για την αγωγη του διαβητη | |
| CY1125247T1 (el) | Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2 | |
| TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
| CY1125114T1 (el) | Συνθεσεις και μεθοδοι για τη μειωση μειζωνων ανεπιθυμητων καρδιαγγειακων συμβαντων | |
| CY1119025T1 (el) | Συνδυασμος δυο αντιιικων για την αγωγη της ηπατιτιδας c | |
| TR201900176T4 (tr) | Anti-TROP2 antikor-ilaç konjugatı. | |
| CY1122449T1 (el) | Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1 | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| CY1117476T1 (el) | Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| CY1122349T1 (el) | Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40 | |
| CY1119174T1 (el) | Συνδυασμος ενος οξειδωτικου και ενος φωτοενεργοποιητη για την επουλωση πληγων | |
| CY1118933T1 (el) | Anti-cxcr1 συνθεσεις και μεθοδοι | |
| CY1123398T1 (el) | Συνθεση συνδυασμου | |
| CY1106824T1 (el) | Σταθερες ενεσιμες συνθεσεις δικλοφενακ | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| BR112012010762A2 (pt) | inibidores de prolil hidroxilalse | |
| CY1119826T1 (el) | Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη | |
| CY1116926T1 (el) | Συνθεση για εισπνοη που περιεχει ακλιδινιο για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας |